论文部分内容阅读
目的观察重组人p53腺病毒注射液(rAd2p53)瘤内注射联合顺铂+紫杉醇方案化疗与单纯化疗对喉癌动物模型的治疗效果,试图为此方法的临床应用提供实验室依据。方法利用喉癌Hep-2细胞系小鼠背部注射建立喉癌的荷瘤动物模型,实验组在荷瘤部位瘤内注射重组人p53腺病毒注射液并静脉注射顺铂+紫杉醇;对照组1单纯瘤内注射p53腺病毒注射液;对照组2单纯静脉注射顺铂+紫杉醇,观察肿瘤治疗前后瘤体大小变化。结果基因联合化疗治疗组肿瘤生长明显受抑制,疗效显著优于单纯基因及单纯化疗组。结论重组人p53腺病毒注射液(rAd2p53)联合顺铂+紫杉醇方案化疗可显著提高喉癌治疗效果。
Objective To observe the therapeutic effect of recombinant adenovirus p53 (rAd2p53) combined with cisplatin plus paclitaxel chemotherapy in the animal model of laryngeal cancer and try to provide a laboratory basis for the clinical application of this method. Methods The tumor-bearing animal model of laryngeal carcinoma was established by injecting the back of laryngeal carcinoma Hep-2 cell line in mice. The experimental group was injected intratumorally with recombinant human p53 adenovirus injection and paclitaxel in the tumor-bearing site. Intratumoral injection of p53 adenovirus injection; control group 2 simple intravenous cisplatin + paclitaxel, tumor size changes before and after treatment. Results The combination of chemotherapy and gene therapy significantly inhibited the growth of tumor, the effect was significantly better than simple gene and chemotherapy group. Conclusion Recombinant human p53 adenovirus injection (rAd2p53) combined with cisplatin + paclitaxel chemotherapy can significantly improve the therapeutic effect of laryngeal cancer.